NCT02041117View on ClinicalTrials.gov

Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging

PHASE4CompletedINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

February 24, 2014

Primary Completion Date

November 6, 2018

Study Completion Date

November 6, 2018

Conditions

Intracranial Arterial Stenosis

Interventions

DRUG

Rosuvastatin

Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.

Trial Locations (1)

Unknown

Beijing Tiantan Hospital affliated to Capital Medical University, Beijing

All Listed Sponsors

lead

Beijing Tiantan Hospital

OTHER

NCT02041117 - Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging | Biotech Hunter | Biotech Hunter